Roivant Sciences
VC Fund
New York, United States
Roivant Sciences is a biopharmaceutical company focused on completing the development of promising late-stage drug candidates.Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. Roivant does this by building Vants - nimble, entrepreneurial biotech andhealthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying the technology. In addition to its biopharmaceutical subsidiaries, Roivant also builds technology-focused Vants focused on improving the process of developing and commercializing medicines.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 45%
Last updated:
For AI agents: llms.txt
Industries Roivant Sciences invests in
Stages Roivant Sciences invests in
Countries Roivant Sciences invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Seed
- $13M–$86M
- Series A
- $21M–$48M
- Series B
- $30M–$40M
Investment Focus
Industry
- Biotechnology 5 (45%)
- Health Care 4 (36%)
- Biopharma 3 (27%)
- Artificial Intelligence 3 (27%)
- Genetics 2 (18%)
Stage
- Seed 2 (18%)
- Series A 2 (18%)
- Series B 2 (18%)
- Post-IPO Equity 2 (18%)
- Pre-Seed 1 (9%)
Country
- United States 7 (64%)
- Brazil 1 (9%)
- Canada 1 (9%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Alex Gasner
Executive Vice President
|
Executive Vice President | Total investments: 2 | Find email | |
Frank Torti
Vant Chair
|
Vant Chair | Total investments: 12 | Find email | |
Matthew Gline
Chief Executive Officer
|
Chief Executive Officer | Total investments: 0 | Find email | |
Mayukh Sukhatme
Chief Investment Officer & President
|
Chief Investment Officer & President | Total investments: 0 | Find email | |
Benjamin Zimmer
President, Roivant Health
|
President, Roivant Health | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Proxima Bio develops programmable medicines that modulate protein interactions to address disease processes. It focuses on creating proximity-modulating therapeutics that direct protein interactions for potential use in conditions such as autoimmune disorders and cancer, expanding the range of targets that traditional drugs cannot easily reach.Proxima Bio combines structural biology, data generation, and machine learning to identify actionable protein-protein interfaces and support the discovery of new therapeutic modalities. The company works with pharmaceutical partners to apply its platform in research collaborations and advance drug discovery pipelines. Proxima Bio’s platform integrates multiple technologies to support the design and discovery of novel proximity-based treatment approaches. | $86.3M / Seed / Jan 13, 2026 | ||
| Psivant Therapeutics is a biotechnology company that offers drug design, biology research, and development services. | $47.5M / Series A / Dec 10, 2025 | ||
| Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential toaddress a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. | $450M / Post-IPO Equity / Jan 13, 2025 | ||
| Lokavant is an IT firm that offers real-time visualizations, risk alerts, artificial intelligence, and human insight services. | $21M / Series A / Dec 07, 2022 | ||
| Medallion streamlines provider network operations through AI-driven automation of credentialing, enrollment, privileging, licensing, monitoring, and provider data management. It employs real-time workflows that adapt to payer rules, state regulations, and provider types to reduce delays and manual workload. The platform automates primary sourceverification, committee-ready credentialing file generation, payer enrollment (including delegated workflows), licensing applications and renewals, continuous monitoring of sanctions and exclusions, and shared credentialing via the CredAlliance network. | $30M / Series B / Nov 03, 2021 | ||
| Gen-t is a platform capable of providing the map of genomic research. Gen-t was founded in 2021 and was headquartered in Sao Paulo, Brazil. | $2M / Pre-Seed / Nov 01, 2021 | ||
| Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Its investigational product candidate, IMVT-1401 (formerly known as RVT-1401), is a novel, fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn). We believe that this product has the potential toaddress a variety of IgG-mediated autoimmune diseases as a subcutaneous injection. | $200M / Post-IPO Equity / Aug 02, 2021 | ||
| Datavant is a health data platform company. We make the world’s health data secure, accessible, and usable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousandsof organizations, more than 70,000 hospitals and clinics, 70% of the 100 largest health systems, and an ecosystem of 500+ real-world data partners.To learn more about Datavant, visit datavant.com. | $40M / Series B / Oct 08, 2020 | ||
| Datavant is a health data platform company. We make the world’s health data secure, accessible, and usable. Datavant drives data connectivity into action by offering a proprietary platform and network that deliver critical solutions across the healthcare ecosystem. Datavant enables more than 60 million healthcare records to move between thousandsof organizations, more than 70,000 hospitals and clinics, 70% of the 100 largest health systems, and an ecosystem of 500+ real-world data partners.To learn more about Datavant, visit datavant.com. | $40.5M / Venture - Series Unknown / Apr 30, 2018 | ||
| Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). They believe that Arbutus' comprehensive HBV pipeline of drugs and drug candidatesoptimally positions us to transform the HBV treatment landscape and to capitalize on the HBV global market opportunity.They are developing a portfolio of drug candidates with multiple mechanisms of action that They believe will result in a combination therapy to cure HBV. Specifically, They seek to effect a cure by targeting the three pillars necessary to develop a curative regimen for HBV. This includes suppressing HBV replication within liver cells, stimulating and reactivating the body’s immune system so that it can mount an effective defense against the virus and eliminating the reservoir of viral genomic material known as covalently closed circular DNA, or cccDNA, that is the source of HBV persistence. | $116.4M / Post-IPO Equity / Oct 02, 2017 | ||
| See all 11 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Roivant Sciences invest in?
Roivant Sciences invests primarily in Biotechnology, Health Care and Biopharma startups, most often at Seed and Series A stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Roivant Sciences invest in?
Roivant Sciences typically joins rounds of $13M–$86M at Seed, $21M–$48M at Series A and $30M–$40M at Series B. These are whole funding-round sizes, not Roivant Sciences's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Roivant Sciences took part in.
How do I contact Roivant Sciences?
Public channels for Roivant Sciences include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Roivant Sciences?
The team at Roivant Sciences includes Alex Gasner (Executive Vice President), Frank Torti (Vant Chair) and Matthew Gline (Chief Executive Officer), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
